RCS - Angle PLC - Parsortix outperforms standard for DTC harvest

AngleAnnouncement

03/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231003:nRSC4311Oa&default-theme=true

RNS Number : 4311O  Angle PLC  03 October 2023

 For immediate release  3 October 2023

 

ANGLE plc ("the Company")

 

PARSORTIX SYSTEM OUTPERFORMS CURRENT LABORATORY STANDARD FOR DISSEMINATED
TUMOUR CELL HARVEST

 

DTCs linked to cancer relapse even after prolonged remission

 

DTCs harvested by the Parsortix system were 'abundant and viable' facilitating
biomarker assessment

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology, today announces the
publication of a study of disseminated tumour cells (DTCs) in bone marrow from
breast cancer patients published in the International Journal of Molecular
Sciences.

 

Researchers at the University of Tübingen, Germany, used the Parsortix(®)
system for the isolation and harvest of DTCs from bone marrow samples in 360
breast cancer patients (clinical stages I-IV) and compared results to the
standard density centrifugation method for DTC detection. The study found that
the Parsortix system was easier to use and yielded significantly higher
numbers of DTCs for further analysis, compared to the standard method for DTC
detection. The isolated DTCs were abundant and viable (alive and undamaged),
which cannot be achieved with the standard method. This provides more and new
analysis options for DTC characterisation including assessment of biomarker
status which is important for targeted treatment selection and prognostic
assessment.

 

DTCs are circulating tumour cells (CTCs) that have left the primary tumour and
travelled in the blood to a distant organ, in this instance bone marrow, where
they can remain dormant before being released at a later date. Release of
these cells into the blood, is thought to be the most likely cause of relapse
for patients who have had a prolonged remission.

 

One-third of breast cancer patients have DTCs already present in the bone
marrow at the time of diagnosis; these patients, as well as patients with
persistent DTCs, have significantly worse clinical outcomes than DTC-negative
patients. Since DTC biomarker status may differ from the primary tumour with
regard to key proliferation and growth receptors such as ER and HER2, the
ability to evaluate these markers on DTCs may enable clinicians to optimise
targeted therapy and reduce the risk of relapse.

 

ANGLE Chief Scientific Officer, Karen Miller, commented:

"We are pleased to share the peer-reviewed publication by the University of
Tübingen that demonstrates consistently high performance of the Parsortix
system for the harvest of DTCs as opposed to CTCs. This is the second study
centre to demonstrate successful enrichment and harvest of DTCs from bone
marrow aspirate highlighting a range of additional potential uses of the
Parsortix system in clinical practice."

 

The research has been published as a peer-reviewed publication in the
International Journal of Molecular Sciences and is available online at
https://angleplc.com/publications/ (https://angleplc.com/publications/) .

 

 

For further information:

 

 ANGLE plc
 Andrew Newland, Chief Executive         +44 (0) 1483 343434

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Joint Broker)      +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 Jefferies (Joint Broker)                +44 (0) 20 7029 8000

 Thomas Bective, Shaam Vora

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

For Research Use Only. Not for use in diagnostic procedures.

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) diagnostic solutions for use in research, drug development
and clinical oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected circulating tumour cell (CTC) harvesting technology known as
the Parsortix(®) PC1 System enables complete downstream analysis of the
sample including whole cell imaging and proteomic analysis and full genomic
and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratories in the UK and the United States.  Services include
custom made assay development and clinical trial testing for pharma.

 

Over 80 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQLLFBXBLBFBK